The actor, who publicly announced his diagnosis earlier this year, spoke on a virtual panel with I Am ALS and writers from the NBC drama: "I have no reason to be in a good spirit at any time, on any ...

Eric Dane is sharing everything about his ALS battle — including the emotional toll that the devastating diagnosis has taken on him. The “Euphoria” actor, 53, gave the latest update on his health ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage ...

People in certain states in America appear to be more likely than others to develop devastating neurological diseases, a new study has indicated. Lou Gehrig's disease—also known as amyotrophic lateral ...

Vor zehn Jahren starb der ehemalige Bundeskanzler Helmut Schmidt im Alter von 96 Jahren in seiner Heimatstadt Hamburg. Ihm zu Ehren ändert der NDR in der Nacht von Freitag auf Samstag sein Programm.

Eric Dane plans on having a spot on the call sheet for as long as possible. In the months since the Greys Anatomy Alum shared he had been diagnosed with amyotrophic lateral sclerosis (ALS) in April, ...

Eric Dane is opening up about his ongoing battle with ALS. The "Grey's Anatomy" star, who revealed he was diagnosed with the degenerative neurological disease in April 2024, told the Washington Post ...

Evidence is emerging that amyotrophic lateral sclerosis (ALS) may have an autoimmune component — a finding that, if confirmed, could shape the development of new therapies and prognostic tools.

High levels of SO2 can be made from burning coal or diesel-operated equipment. A major pollutant from mining fossil fuels has been linked to an increased risk of amyotrophic lateral sclerosis (ALS), ...

Four investigational ALS treatments failed in phase II studies, but CNM-Au8 and pridopidine showed promising trends. The platform trial pooled placebo data across studies, allowing more ALS patients ...